#USA #San Diego #Oncolytics Biotech #pelareorep #Alumni Capital

Oncolytics Biotech® Partners with Alumni Capital for Pelareorep Development

On April 10, 2025, Oncolytics Biotech® Inc., known for its innovative immunotherapy solutions, announced a significant partnership with Alumni Capital LP. This collaboration focuses on advancing the clinical development of their promising candidate, pelareorep, through a share purchase agreement (SPA) designed to provide essential funding while minimizing dilution for existing shareholders.

The Share Purchase Agreement Explained

Under the terms of the SPA, Oncolytics Biotech has secured the right to sell up to $20 million worth of common stock over a period of 15 months. This sale will occur at market-dependent prices, allowing Oncolytics to strategically manage the timing and volume of shares sold. Crucially, this approach provides the flexibility needed to respond effectively to pelareorep’s clinical milestones, which is essential as the company navigates its development pipeline.

Alumni Capital's commitment to this agreement demonstrates confidence in Oncolytics’ vision for growth and innovation in the oncology space. As part of the agreement's structure, Oncolytics issued Alumni 816,326 commitment shares, with the possibility of issuing an additional amount based on the execution of purchase notices.

A Focus on Clinical Milestones

The funds raised through this agreement are earmarked for advancing pelareorep towards critical clinical milestones. Pelareorep has shown significant promise in treating various cancers, particularly in randomized Phase 2 trials for metastatic breast cancer and ongoing studies for pancreatic cancer. This stream of funding will facilitate the logistics and operations of ongoing and upcoming clinical trials, helping ensure Oncolytics remains at the forefront of cancer immunotherapy.

Regulatory Approvals and Market Listing

In conjunction with the SPA, Oncolytics biotech shares have been conditionally approved for listing on the Toronto Stock Exchange (TSX). The company also filed required notices with Nasdaq, enhancing its visibility and potentially broadening its shareholder base. It’s important to note that these common shares will not be available for purchase in Canada or through TSX commands to ensure compliance with regulatory standards.

Significance of This Agreement

The agreement represents a judicious financial strategy to fund the promising clinical journey of pelareorep without compromising shareholder equity. By granting control over the sales process to Oncolytics, the company can finely tune its capital influx according to its development timeline, ensuring consistent funding as it meets various operational needs and clinical ambitions. Moreover, the absence of associated warrants or derivatives further streamlines this funding approach, making it an attractive proposition for all stakeholders involved.

The Future Outlook for Oncolytics and Pelareorep

Oncolytics Biotech is committed to redefining treatment paradigms through its cutting-edge research and innovative therapies. With pelareorep demonstrating favorable results in treating notoriously hard-to-target tumors, Oncolytics is positioning itself as a leader in the immunotherapy field. The new funding avenue via Alumni Capital is set to propel the research and clinical advancement of pelareorep, ultimately aiming to bring a novel and effective cancer treatment to market. As this partnership unfolds, the development of pelareorep will be closely monitored by industry experts, investors, and patients eager for hope in cancer treatment solutions.

Through these strategic moves, Oncolytics Biotech aims not only to secure financial stability but also to enhance shareholder value and establish itself firmly within the competitive landscape of oncology therapeutics. With favorable data emerging from ongoing studies, the company is well poised for a transformative phase in its operational trajectory.

Conclusion

The collaboration between Oncolytics Biotech and Alumni Capital signifies a promising venture into the future of cancer treatments. As pelareorep moves forward, this partnership will likely be heralded as a pivotal moment in the evolution of Oncolytics and its quest to deliver innovative solutions that address unmet medical needs in oncology.